NEW YORK (GenomeWeb News) – The Translational Genomics Research Institute said today that it will partner with the Barbara Ann Karmanos Cancer Institute and several other partners in a $6 million study that will use genomics and other approaches to aid in the development of skin cancer therapies.

e2v aerospace and defense, Inc. and Maxim Integrated Products, Inc. announced today an agreement for e2v to extend the life of a wide variety of Maxim ICs in hermetic and metal can packages used in an array of military and aerospace programs.

GeoVax and Vivalis signed a potentially €4 million biomanufacturing agreement for the production of GMP-grade materials for the latter’s MVA-based vaccines.

VisionGate announced a collaboration with the Sheba Medical Center in Israel focused on evaluating the Arizona-based firm’s LuCED™ (lung cell evaluation device) test in conjunction with x-ray computed tomography screening for the detection of early lung cancer.

Metabolon, Inc., a diagnostics and services company offering the industry’s leading biochemical profiling technology, announced today that it has opened a new metabolomics lab in Shanghai, China in collaboration with Shanghai Jiao Tong University (SJTU).

Health Discovery Corporation (OTCBB: HDVY) today announced its agreement with the U.S. Preventive Services Task Force’s (USPSTF) stance against the use of the prostate-specific antigen (PSA), a test used by 90 percent of U.S. men to screen for prostate cancer.

Aircraft Medical ("Aircraft"), the UK medical devices company, today announces that it has signed an exclusive agreement with Covidien (NYSE: COV), a leading global provider of healthcare products with 2010 revenue of $10.4 billion, and 41,000 employees worldwide.

Scientists at deCODE Genetics and academic collaborators from Iceland, Norway, Denmark, the Netherlands and the USA today report the discovery of low frequency variants in the human genome that associate with risk of gout, a common inflammatory arthritis, and serum uric acid levels.